TENAX THERAPEUTICS, INC. Cash Flow Statement
TENX|7 years of annual SEC 10-K data (FY2012-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 7 fiscal years. All figures from audited SEC 10-K filings.
TENAX THERAPEUTICS, INC. used $15M in operating cash flow in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.24 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|
| Net Income | -$17.6M | -$7.7M | -$19.5M | -$19.5M | -$9.4M | -$15.7M | $10.4M |
| Depreciation & Amortization | - | $8.0K | $150.5K | $150.5K | $148.8K | $206.7K | $311.0K |
| Operating Cash Flow | -$14.8M | -$5.9M | -$9.3M | -$9.3M | -$4.9M | -$8.3M | -$8.4M |
| Capital Expenditures | - | - | $9.8K | $9.8K | $17.2K | $17.7K | $240.8K |
| Free Cash Flow | - | - | -$9.3M | -$9.3M | -$4.9M | -$8.3M | -$8.6M |
| FCF Margin | - | - | -5833.8% | -5833.8% | -414.7% | -2280.5% | -8378.6% |